Video

Dr. Weber discusses cardiovascular safety of vibegron in patients with OAB

Author(s):

Urology Times staff

“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.

In this video, Michael A. Weber, MD, discusses the takeaways of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Ruben Olivares, MD, answers a question during a Zoom video interview
Related Content
FDA approves integrated sacral neuromodulation system for urinary urge incontinence
June 18th 2025

FDA approves integrated sacral neuromodulation system for urinary urge incontinence

Hannah Clarke
The approval is supported by landmark results from the pivotal phase 2 SANS-UUI trial.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
May 9th 2025

Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
May 1st 2025

Safety, efficacy of vibegron sustained in men with OAB treated for BPH

Benjamin P. Saylor
The investigators reported an overall incidence of AEs of 29.6%.
© 2025 MJH Life Sciences

All rights reserved.